SEC Form 4 · accession 0001127602-19-005195
LABCORP HOLDINGS INC. · LH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John D Ratliff
Officer — CEO, Covance Drug Development
Period of report
Feb 7, 2019
Accepted (ET)
Feb 11, 2019 · 7:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000920148
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 7, 2019 | M | 1,863 | — | A | 11,261 | D | |
| Common Stock | Feb 7, 2019 | F | 556 | $147.46 | D | 10,665 | D | |
| Common StockF3 | holding | — | — | — | 40 | I | By revocable trust | |
| Common StockF4 | holding | — | — | — | 80 | I | By irrevocable trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF6,F1,F5 | — | Feb 7, 2019 | M | 1,863 | D | — | — | Common Stock | 1,863 | 24,474 | D |
Explanation of responses
- F1Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- F2Stock withholding to satisfy tax withholding obligations.
- F3In prior Section 16 reports shares were previously also reported in shares shown as directly owned.
- F4The reporting person is not a trustee of the irrevocable trust and disclaims beneficial ownership of the shares.
- F5The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/7/18.
- F6This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
Remarks
Exhibit 24 - Power of Attorney